Curvebeam Ai Ltd. · ASX:CVB
Curvebeam Ai — Investor Presentation (January 2025)
10 slides from Curvebeam Ai's investor presentation, Jan 29, 2025
Slide 1: Quarterly 4C Conference Call
QUARTERLY 4C CONFERENCE CALL 29th of January 2025
Slide 2: Disclaimer
DISCLAIMER Introduction THIS DOCUMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, Forward looking statements DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA OR TO ANY The information given in this presentation is given for illustrative purposes only
Slide 3: 4C Summary of Key Activities
4C SUMMARY OF KEY ACTIVITIES • CurveBeam AI received purchase orders (POs) for ten (10) devices in Q2 FY25, representing around A$5m in future sales for the quarter. Compared with the prior corresponding period of four (4) devices in Q2 FY24, this is a 150% increase in orders. Total device purchase
Slide 4: Quarterly Purchase Orders Analysis
QUARTERLY PURCHASE ORDERS ANALYSIS Device Purchase Orders FY24Q1 FY24Q2 FY24Q3 FY24Q4 FY25Q1 FY25Q2 US 2 2 2 5 1 8 Rest of World 1 2 3 5 2 2 Total 3 4 5 10 3 10 Total Purchase Orders by Qtr by Region 12 10 10 10 8 8 6 5 5 5 4 TM 4 3 3 3 2 2 2 2 2 2 2 1 1 0 FY24Q1 FY24Q2 FY24Q3 FY24Q4 FY25Q1 FY25Q2 D
Slide 5: Quarterly Purchase Orders Analysis
QUARTERLY PURCHASE ORDERS ANALYSIS HiRise Purchase Orders FY24Q1 FY24Q2 FY24Q3 FY24Q4 FY25Q1 FY25Q2 US 2 2 0 4 0 7 Rest of World 1 2 3 3 2 1 Total 3 4 3 7 2 8 HiRise Purchase Orders by Qtr by Region 9 8 7 6 5 4 3 2 TM 1 0 FY24Q1 FY24Q2 FY24Q3 FY24Q4 FY25Q1 FY25Q2 US Rest of World Total 5
Slide 6: Cashflows from Operations
Cashflows from Operations • Cash used in operations for Q2 FY25 was A$2.7m versus A$5.3m in Q2 FY24 (pcp);and A$4.7m in Q1 FY25. Receipts from customers was the highest recorded to date for a quarter at A$2.6m, up from A$1.3m in Q2 FY24 (pcp) and A$2.4m in Q1 FY25. • Cash outflows totaled A$7.1m dow
Slide 7: Enhanced HiRise Project for Robotic Surgical Systems
ENHANCED HIRISE™ PROJECT FOR ROBOTIC SURGICAL SYSTEMS • CurveBeam AI has completed the development of the Enhanced HiRise™ platform and is now FDA 510(k) cleared. • Enhanced HiRise™ WBCT scans, with higher energy X-Ray source, allows key anatomical landmarks to be identified in larger patients. • Ke
Slide 8: BMD SaaS MDCT Module Update
BMD SAAS MDCT MODULE UPDATE Multidetector CT (MDCT) • As discussed in the quarterly activity report for Q1 FY 25, the Company’s revised BMD regulatory strategy is to clear the first BMD module on multidetector CT (MDCT) scanners, the primary technology used today for custom cut guides. • This change
Slide 9: In Closing
IN CLOSING • Received purchase orders (POs) for ten (10) devices in Q2 FY25 (around A$5m in future sales). A record quarter (FY25 Q2) for purchase orders for the HiRise™. • A formal agreement with Stryker Australia and New Zealand expands commercial arrangements with Stryker into CurveBeam AI’s home
Slide 10: Definitions
DEFINITIONS CurveBeam AI’s key metrics are defined and interpreted as follows: • Purchase order – a signed purchase order (PO) for a CT scanner (device). The Company considers POs to be a key metric as it reflects actual sales at any given time. • Receipts from customers – any cash consideration rec